Niaoduqing Granules in Older Adults With Chronic Kidney Disease Not on Dialysis
Tests Niaoduqing Granules in older adults with chronic kidney disease, not on dialysis.
Plain-language title generated from the registry record
Registry title: Niaoduqing Granules in Older Adults With Impaired Kidney Function
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 4
Where in China
- Huashan Hospital, Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Huashan Hospital
- Trial code
- NCT07741292
- Record updated
- 3 August 2026
- Original description
This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes.Read full original descriptionShow less
A Study of the Clinical Benefits of Niaoduqing Granules in Older Adults With Impaired Renal Function
This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes.
Participants will receive 5 g of Niaoduqing Granules three times daily after meals for 12 months, while continuing their usual treatment for chronic diseases as directed by their physicians. Kidney function, laboratory results, nutritional status, frailty, cardiovascular and cerebrovascular events, and survival will be assessed during follow-up. Blood, urine, and stool samples will also be collected to study changes in gut microorganisms and blood metabolites that may help explain how Niaoduqing Granules affect health. Participants will be followed for up to 60 months.
Inclusion: Participants with stage 3 to 5 chronic kidney disease who are not receiving dialysis; Age older than 60 years; The participant or a family member has sufficient literacy and is able to comply with dietary diary recording and other study-related examinations; The underlying cause of chronic kidney disease is clinically stable.
Exclusion: Use of immunosuppressive therapy, including cyclosporine or tacrolimus, within the 3 months before cohort enrollment, or use of corticosteroids at a dose equivalent to more than 10 mg/day of prednisone; Current participation in, or participation within the previous month in, another study related to diet or medication; Malignancy, severe cardiovascular disease, osteoporosis, or severe hematopoietic system disease; Active infection, defined as C-reactive protein greater than 10 mg/L, or current use of nephrotoxic medications; Limb paralysis or major limb impairment; Severe gastrointestinal disease affecting nutrient absorption; Known allergy to Niaoduqing Granules; Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.